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Many case reports have been reported that botulinum toxin 
type A (BoNT-A) injections are effective for controlling invol-
untary orofacial movements and secondary bruxism in patients 
with movement disorders, and awake bruxism (e.g., clenching 
habit).11-15 Other studies with only SB patients showed that 
BoNT-A injections can reduce the frequency of jaw motor 
events,16 decrease bruxism-induced pain levels,16,17 and is 
Study Objectives: To investigate the effects of botulinum toxin 
type A (BoNT-A) injection on jaw motor episodes during sleep 
in patients with or without orofacial pain who did not respond 
to oral splint treatment.
Methods: Twenty subjects with a clinical diagnosis of SB 
completed this study. Ten subjects received bilateral BoNT-A 
injections (25 U per muscle) into the masseter muscles only 
(group A), and the other 10 received the injections into both 
the masseter and temporalis muscles (group B). Video-
polysomnographic (vPSG) recordings were made before 
and at 4 weeks after injection. Rhythmic masticatory muscle 
activity (RMMA) and orofacial activity (OFA) were scored and 
analyzed for several parameters (e.g., frequency of episodes, 
bursts per episode, episode duration). The peak amplitude of 
electromyographic (EMG) activity in the two muscles was also 
measured.
Results: BoNT-A injection did not reduce the frequency, 
number of bursts, or duration for RMMA episodes in the two 
groups. The injection decreased the peak amplitude of EMG 
burst of RMMA episodes in the injected muscles (p < 0.001, 
repeated measure ANOVA) in both groups. At 4 weeks after 
injection, 9 subjects self-reported reduction of tooth grinding 
and 18 subjects self-reported reduction of morning jaw 
stiffness.
Conclusions: A single BoNT-A injection is an effective 
strategy for controlling SB for at least a month. It reduces 
the intensity rather than the generation of the contraction in 
jaw-closing muscles. Future investigations on the effi cacy 
and safety in larger samples over a longer follow-up period 
are needed before establishing management strategies for SB 
with BoNT-A.
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Sleep bruxism (SB) is defi ned as a stereotyped oromandibular activity during sleep characterized by teeth grinding and 
clenching.1,2 SB is one of the common sleep related movement 
disorders, with a prevalence of self-reported tooth grinding of 5% 
to 8% in the adult population.3,4 In the fi eld of dentistry, SB has 
been recognized to be related to teeth destruction, dental pros-
theses/implant failure, pain in the teeth, jaw, masticatory muscle, 
and temporomandibular joint (TMJ), or headache.1,5,6 These dental 
problems can be associated with the frequent and intense contrac-
tions of the jaw-closing muscles during sleep.7,8 There are various 
treatment modalities for the management of SB such as oral 
splint, behavioral approaches, and pharmacological management; 
oral splint is the most commonly used treatment. The previous 
studies reported that the EMG activity of masseter muscle during 
sleep were decreased, increased, or not changed after oral splint 
usage.9,10 Currently, oral splint is considered as the fi rst choice for 
protecting teeth and prostheses from damages. Although various 
treatment modalities, such as behavioral approaches and pharma-
cological management were tested for SB, there were no effective 
treatment strategies for controlling intense contractions of masti-
catory muscles during sleep in SB patients.1
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BRIEF SUMMARY
Current Knowledge/Study Rationale: Botulinum toxin type A (BoNT-A) 
has been used for managing involuntary orofacial movements and sec-
ondary bruxism in patients with movement disorders, but its usefulness 
and objective effects on sleep bruxism (SB) have not been evaluated 
using objective measures. The aim of this study was to investigate the 
effects of intramuscular BoNT-A injection on orofacial motor events dur-
ing sleep in patients with clinical diagnosis of SB.
Study Impact: A single injection of BoNT-A into jaw-closing muscles is 
an effective strategy for controlling SB for at least a month. It reduces the 
intensity rather than the generation of the contraction in the jaw-closing 
muscles. Establishing management of SB with BoNT-A awaits further 
studies on larger samples over a longer follow-up period.
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equally effective in pain reduction when compared with oral 
splint.17,18 The result of these studies and case reports were 
based on the subjective evaluation of SB, not on the objec-
tive assessment using electromyography (EMG) or polysom-
nography (PSG). A study using portable electromyographic 
(EMG) device showed that the counts of sleep related mastica-
tory EMG bursts, detected by the pre-defined threshold, were 
significantly reduced after a single injection of BoNT-A in the 
masseter muscle.19 However, it remains unclear how BoNT-A 
injection works specifically for sleep-related masticatory EMG 
activity, as a variety of jaw motor activities occur in association 
with transient arousal changes during sleep.20 Video-polysom-
nography (vPSG) can be a useful tool allowing discrimina-
tion of the types of sleep-related masticatory EMG events.2 
In previous case reports and studies, some cases injected 
BoNT-A into the masseter muscle only,13-15,17,18 and others into 
both the masseter and temporalis muscles.10,11,15 The masseter 
and temporalis muscles are synergetic muscles and activated 
during teeth grinding and clenching; however, there have been 
no studies assessing the difference between the choices or the 
combination of the injected muscles for motor activity control 
of the jaw during sleep.
Therefore, the aims of this study were to investigate the effects 
of intramuscular BoNT-A injection on jaw motor episodes using 
vPSG. In addition to the use of vPSG, we compared the effects 
of BoNT-A on jaw motor episodes between the injection sites 
(i.e., the masseter muscle injection only versus injection of both 
masseter and temporalis muscles).
METHODS
Subjects
The protocol of this study was undertaken with the approval 
of Korea Food & Drug Administration and Institutional Review 
Board of the Yonsei University Dental Hospital. All subjects 
were informed of the nature of the study, and written consent 
was obtained from each participant.
Twenty-four subjects (M: 10; F: 14, age: 20.2-38.7 years) were 
selected from among outpatients at the Department of Orofacial 
Pain and Oral Medicine, Yonsei University Dental Hospital. All 
subjects were interviewed by one clinician (YJS), who docu-
mented his or her age, gender, medical history, and drug history 
at the first visit. The subjects had the following clinical signs 
and symptoms for SB: (1) a history of tooth grinding occur-
ring ≥ 3 nights per week, (2) experience of morning jaw stiff-
ness, and (3) clinical presence of tooth wear.1,2 They had been 
using an oral splint for SB with orofacial pain or without orofa-
cial pain. Fifteen patients had jaw muscle pain, and 11 patients 
had a TMJ click sound (evaluated by clinical examination). 
The subjects had been treated with an oral splint for control-
ling SB or orofacial pain for periods ranging from 3 months to 
10 years. However, they still self-reported bruxism activity and 
showed moderate to severe wear facets on their oral splint. So, 
we decided to consider an additional management modality, 
i.e., BoNT-A injection. The following exclusion criteria were 
applied: (1) previously received BoNT-A injection into both 
the masseter and temporalis muscles, (2) taking medications 
affecting muscle relaxation (e.g., antiepileptic drugs, benzodi-
azepines), (3) infectious skin lesion at the site of injection, (4) 
allergy to BoNT-A, (5) neuromuscular disease, and (6) pregnant 
females. The subjects were randomly assigned into 2 groups; 
Group A: 12 subjects who received bilateral BoNT-A injections 
into the masseter muscle only, and Group B: the other 12 who 
received bilateral BoNT-A injections into both the masseter and 
temporalis muscles. The subjects were requested not to take any 
other treatments or medications that would affect the muscles 
and not to use an oral splint during the time period of this study.
Botulinum Toxin
The BoNT-A (Neuronox, Medytox Inc., Seoul, Korea) was 
supplied as a freeze-dried powder of 200 U, and was recon-
stituted with 4 mL of sterile saline to a concentration of 5 
U/0.1 mL. A dose of 25 U of BoNT-A was injected into each 
muscle using a 1-mL syringe with a 29-gauge, 0.5-inch needle. 
BoNT-A was injected into 3 sites of each subject’s masseter and/
or temporalis muscles depending on the experimental group. 
The BoNT-A injection sites are shown in Figure 1.21-23 In the 
masseter muscle, the first site was the inferior, prominent part 
of the masseter muscle that was observed when the subject was 
asked to clench, and the other 2 sites formed a triangle 10 mm 
away from the first site (Figure 1A). In the temporalis muscle, 
the first site was the prominent part of the anterior temporalis 
muscle that was observed when the subject was asked to clench, 
which was parallel to eyebrow. The other 2 sites were 10 mm, 
20 mm away from the first site posteriorly (Figure 1B).
Video-Polysomnography
All subjects were studied in the sleep laboratory for 2 nights. 
The first night was before BoNT-A injection (baseline PSG 
recording) and the second night was 4 weeks after BoNT-A 
injection (follow-up PSG recording).
Prior to sleep recordings, each patient completed an Epworth 
Sleepiness Scale questionnaire and a series of oromotor tasks to 
Figure 1—BoNT-A injection sites.
The sites of BoNT-A injections in the masseter (A) and temporalis (B) 
muscles. BoNT-A was injected into 3 sites of masseter and/or temporalis 
muscles. (A) In the masseter muscle, the 3 injection sites formed a 
triangle 10 mm apart with a reference of the inferior, prominent part of 
the masseter muscle when the subject clenched the teeth. (B) In the 
temporalis muscle, the 3 injection sites were arranged posteriorly, in 
parallel to eyebrow, from the site at the prominent part of the anterior 
temporalis muscle when the subject clenched the teeth.
A B
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enable signal recognition and calibration of EMG amplification. 
Biocalibration for the masseter and temporalis muscles EMG 
recordings included maximal voluntary clenching (MVC), 
lateral jaw movement, tooth tapping, and jaw opening. The 
sleep recordings commenced at 22:30 (± 30 min) and ended 
upon the subject’s spontaneous awakening or at 07:30. PSG 
montage included electrooculography, electroencephalography 
(EEG), abdominal and chest bands, pulse oximetry, and EMG 
recordings from the submental and bilateral tibialis anterior 
muscles, as well as from the bilateral masseter and temporalis 
muscles. Video (focused on the head and neck area) and audio 
recordings were made simultaneously. All signals were ampli-
fied and recorded at a sampling rate of 200 Hz and stored for 
off-line analysis using Twin-PSG software (Grass Technolo-
gies, West Warwick, RI, USA).
Data Analysis
Sleep Variables
Sleep stages and microstructures, apnea and hypopnea events 
and periodic leg movements in sleep were scored according to 
the standard criteria.1 The following sleep parameters were calcu-
lated: total sleep time, sleep stage, sleep efficiency, sleep latency, 
arousal index, frequency of awakenings per hour of sleep, apnea-
hypopnea index, and periodic limb movement index.
Scoring Jaw and Orofacial Motor Activity (OFA)
A single observer (YJS) scored jaw and orofacial motor 
events under a guidance of another coauthor (TK). The observer 
was blinded to the subject and the experimental group to which 
the subject belonged. Jaw motor activity was scored based on 
the EMG recordings of the masseter and temporalis muscles 
and the audio-video recordings. Most episodes of jaw motor 
activity were shown in the 2 muscles simultaneously, and the 
types of each episode in the 2 muscles were same. Jaw motor 
episodes related to the diagnosis of SB were scored as rhythmic 
masticatory muscle activity (RMMA) that included phasic (3 
EMG bursts with durations of 0.25-2.0 sec), mixed types (both 
phasic and tonic bursts), and isolated tonic bursts (EMG bursts 
lasting > 2.0 sec).24,25 These episodes were separated by inter-
vals > 3 sec. However, scoring criteria for RMMA episodes 
were modified because BoNT is known to decrease the ampli-
tude of EMG burst in the injected muscles.26 In fact, it was 
difficult for us to use MVC as a reference for normalizing the 
amplitude of EMG bursts in the injected muscles on the follow-
up night. Accordingly, phasic and mixed type episodes were 
scored first based on the observable jaw movements in audio-
video records and then confirmed with EMG traces regardless 
of amplitude criteria. Since it was difficult to detect the isolated 
tonic bursts by audio-video recordings, we used the threshold 
criteria for tonic episodes in the baseline and follow-up nights: 
EMG amplitude with 20% MVC on the baseline night was 
used.19,24 For RMMA episodes, the number of episodes per 
hour of sleep (RMMA index), bursts per hour, the number of 
bursts per episode, the number of episodes with sound, and the 
mean duration were calculated. In addition to these episodes, 
OFAs including lip sucking, head movement, chewing-like 
activity, swallowing, and eye opening were scored using audio-
video.27 The number of OFAs per hour of sleep was calculated. 
In addition to the above counts, the peak amplitude of EMG 
burst of the masseter and temporalis muscles during RMMA 
episodes were measured by ruler on the screen and maximum 
peak value was determined for each episode.
Clinical Symptoms
All subjects were asked to answer questions about subjec-
tive symptoms 4 weeks after BoNT-A injection: (1) how has the 
teeth grinding been changed since the injection? and (2) how 
has the sensation of morning jaw stiffness been changed after 
the injection? There were 3 possible responses to the first ques-
tion: decreased, increased, and no change; the second question 
was answered with a percentage value.
Statistics
Except where stated otherwise, data are presented as 
mean ± standard deviation. The Kolmogorov-Smirnov 
normality test was applied to our data. The data which were 
not normally distributed (Kolmogorov-Smirnov test: p < 0.05) 
underwent log-transformation to achieve close to normal distri-
bution. Two-sample t-test and paired t-test were used to deter-
mine whether differences existed within the groups. Repeated 
measure ANOVA was used to determine whether differences 
existed between the groups. For the evaluation of sleep vari-
ables, two-sample t-test and Mann-Whitney U test were used 
to determine whether differences existed between the groups 
before injection, and paired t-test and Wilcoxon signed-rank 
test were used to determine whether differences existed within 
the groups, depending on the data distribution. The χ2 test was 
used to compare the differences according to sex, masticatory 
muscle pain, and clinically subjective symptoms between the 
groups. The level of statistical significance was set at p < 0.05. 
The SPSS statistical package (version 18.0, SPSS, Chicago, IL, 
USA) was used for all statistical analyses.
RESULTS
Among 24 subjects, 2 subjects dropped out because they 
were unavailable for a follow-up PSG recording. Two other 
subjects did not exhibit a RMMA at the baseline PSG recording. 
Thus, data of 20 subjects (25.8 ± 5.1 years; range, 20.2-38.7 
years; 10 from group A and 10 from group B) were used for the 
analysis. The baseline characteristics of the subjects are listed 
in Table 1. Body mass index was the only characteristic that 
differed significantly between the 2 groups.
Sleep Variables
Data for the sleep variables are given in Table 2. Sleep vari-
ables did not change significantly between baseline and follow-
up in the groups except for the percentage of REM sleep in 
group A. No group difference was noted for sleep variables (all 
variables were p > 0.05).
Jaw Motor Activity Variables
Data for the parameters of RMMA episodes are given in 
Table 3. None of these parameters differed significantly between 
groups A and B at baseline (all variables were p > 0.05). Phasic 
and mixed types were scored for 65.06% and 16.19% of RMMA 
episodes before BoNT-A injection. None of the parameters for 
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RMMA episodes were significantly decreased after BoNT-A 
injection in both groups. Intergroup comparison revealed that 
none of the parameters differed significantly between groups A 
and B after injection. When both groups were pooled, RMMA 
index (F = 0.170, p = 0.685), bursts per hour (F = 1.891, 
p = 0.186), bursts per episode (F = 0.070, p = 0.795), episodes 
with sound (F = 0.040, p = 0.844), and mean episode duration 
(F = 0.266, p = 0.613) did not significantly decreased from 
baseline to follow-up recording.
Peak Amplitude of EMG Burst
Data for the change in peak amplitude of EMG burst are 
given in Table 4. Before BoNT-A injection, the peak ampli-
tude of EMG burst of the masseter and temporalis muscles 
during MVC and RMMA episodes did not differ significantly 
between the groups A and B (all variables were p > 0.05). The 
peak amplitude of EMG burst of BoNT-A injected muscles 
were significantly decreased in both groups. In group A, the 
amplitude of EMG bursts of the masseter muscle during MVC 
(MVC MA) was decreased by 66.9%, and during RMMA 
episodes (RMMA MA) was decreased by 61.7%, while tempo-
ralis muscle during MVC (MVC TE) and RMMA episodes 
(RMMA TE) did not differ before and after injection. In group 
B, the amplitude of EMG burst of the 2 muscles during MVC 
and RMMA episodes was significantly decreased after injec-
tion: the MVC MA was decreased by 56.0%, RMMA MA by 
68.5%, MVC TE by 44.8%, and RMMA TE by 62.1%. Inter-
group comparisons revealed that the MVC TE (F = 8.342, 
Table 1—Characteristics of the subjects
Group A
(n = 10)
Group B
(n = 10) p
Age, yearsa 23.90 ± 3.11 27.70 ± 6.15 0.104
Sex (n)b F: 7, M: 3 F: 6, M: 4 0.639
BMI, kg/m2a 20.43 ± 1.68 22.48 ± 1.87 0.019
ESS scorea 8.10 ± 4.43 11.80 ± 3.71 0.058
Masticatory muscle pain (n)b 8 7
Only in masseter muscle (n) 5 5
Only in temporal muscle (n) 0 0 0.608
In both muscles (n) 3 2
TMJ click sound (n)c 6 5
Morning jaw stiffness (n) 10 10
BMI, body mass index; ESS, Epworth Sleepiness Scale; TMJ, 
temporomandibular joint. aData are presented as mean ± standard 
deviation (two-sample t-test). bThe data were analyzed by χ2 test. 
cTMJ click sound was evaluated by clinical examination. p < 0.05 was 
considered significant (bold type).
Table 3—Variables for RMMA episodes
MA injection (Group A) MA+TE injection (Group B)
p†Pre Post p* Pre Post p*
RMMA index (/h)a 3.27 ± 1.41 2.82 ± 2.47 0.485 2.81 ± 1.38 2.88 ± 2.59 0.915 0.573
Episode properties
Bursts/hb 10.10 (6.27, 23.52) 6.82 (0.51, 59.06) 0.311 11.96 (2.54, 50.45) 12.45 (0.00, 47.12) 0.395 0.997
Bursts/episodea 4.07 ± 1.11 4.69 ± 2.80 0.407 5.02 ± 1.78 4.72 ± 3.05 0.766 0.457
Episodes with soundb 0 (0, 5) 0 (0, 18) 0.592 0 (0, 24) 0 (0, 25) 0.175 0.252
Episode durationa 5.67 ± 1.22 5.99 ± 2.99 0.722 6.82 ± 1.37 5.79 ± 3.31 0.358 0.339
RMMA, rhythmic masticatory muscle activity; MA, masseter muscle; TE, temporalis muscle. aData are presented as mean ± standard deviation (paired t-test). 
bData are presented as median (range) values and underwent log transformation for normal distribution. *Comparison for the change between pre- and post-
BoNT-A injection in each group using paired t-test. †Intergroup comparison for the change between pre- and post-injection (repeated-measures ANOVA).
Table 2—Sleep variables
Sleep variables
MA injection (Group A) MA+TE injection (Group B)
p†Pre Post p Pre Post p
Total sleep time (min)a 352.57 ± 29.29 340.45 ± 26.62 0.431 335.76 ± 36.01 338.80 ± 51.22 0.827 0.458
Stage N1 (%)a 12.21 ± 6.49 11.26 ± 1.26 0.703 15.58 ± 5.58 14.57 ± 5.20 0.662 0.986
Stage N2 (%)a 61.86 ± 1.86 63.67 ± 3.67 0.565 58.41 ± 8.41 59.01 ± 9.01 0.815 0.761
Stage N3 (%)b 2.20 (0.00, 31.30) 11.00 (0.00, 28.20) 0.906 8.10 (0.00, 16.50) 2.00 (0.00, 21.20) 0.441 0.684
Stage REM (%)a 16.60 ± 6.60 14.38 ± 4.38 0.026 17.66 ± 7.66 19.72 ± 9.72 0.393 0.097
Sleep efficiency (%)a 92.96 ± 7.15 93.88 ± 8.33 0.853 91.03 ± 8.78 90.73 ± 8.41 0.903 0.822
Sleep latency (min)a 7.00 ± 7.89 3.25 ± 3.23 0.196 5.40 ± 3.55 4.60 ± 4.34 0.581 0.342
Arousal indexa 16.50 ± 8.11 15.78 ± 7.47 0.768 19.25 ± 7.99 23.08 ± 5.22 0.050 0.129
Awakenings (/h)a 2.43 ± 2.04 1.73 ± 1.37 0.317 2.63 ± 1.53 4.13 ± 2.76 0.091 0.092
AHIb 0.10 (0.00, 2.30) 0.00 (0.00, 0.90) 0.317 0.00 (0.00, 21.50) 0.00 (0.00, 11.70) 0.343 0.912
PLMs indexb 0.00 (0.00, 2.60) 0.00 (0.00, 0.00) 0.721 0.00 (0.00, 12.80) 0.00 (0.00, 31.30) 0.317 0.481
MA, masseter muscle; TE, temporalis muscle; AHI, apnea-hypopnea index; PLMs, periodic limb movements. aData are presented as mean ± standard 
deviation (paired t-test). bData are presented as median (range) (Wilcoxon signed-rank test). †Intergroup comparison for the change between pre- and post-
injection (two-sample t-test and Mann-Whitney U test). p < 0.05 was considered significant (bold type).
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p = 0.010) and RMMA TE (F = 5.998, p = 0.025) differed 
significantly between groups A and B, whereas the other 
amplitude parameters did not.
Orofacial Activity
There were no significant differences in the occurrence of 
OFAs between baseline and follow-up recordings (Table 5).
Subjective Symptoms
Data for the clinically subjective symptoms at a follow-up 
recording are given in Table 6. Four of 10 subjects in group 
A and 5 of 10 in group B self-reported reduction of tooth 
grinding during sleep. These 9 subjects with a self-reported 
decrease of tooth grinding had a significantly higher RMMA 
index (3.83 ± 1.50/h) compared to other 11 subjects who self-
reported no change (2.38 ± 0.87/h; p = 0.015). The reduction 
in the sensation of morning jaw stiffness after BoNT-A injec-
tion was 47.50% ± 15.86% in group A and 57.50% ± 30.30% 
in group B. Fourteen subjects reported discomfort associated 
with a decrease in masticatory force after BoNT-A injection. 
The reduction in the sensation of masticatory force after injec-
tion was 30.00% ± 17.64% in group A and 40.50% ± 18.33% 
in group B. The above variables did not differ between 
groups A and B. Among 14 subjects who reported a 
decrease in masticatory force, only 3 subjects complained 
of masticatory difficulties.
DISCUSSION
This is the first study to evaluate the effect of a single 
BoNT-A injection on SB using vPSG. The results showed 
that BoNT-A injection to the masseter and temporalis muscles 
did not change the occurrence of RMMA episodes and OFAs. 
However, in both groups, the amplitude of EMG burst during 
RMMA episodes was significantly decreased for the muscles 
that received BoNT-A injection. Therefore, the findings of this 
present study confirm that the effect of BoNT-A on jaw motor 
activity during sleep is characterized by a reduction of the 
intensity of the contractions in the injected muscles rather than 
by the reduction of event occurrence.
Effects on Jaw Motor Activity during Sleep
In this study, BoNT-A injections did not decrease the RMMA 
episodes per hour (e.g., RMMA index). In addition, other vari-
ables for RMMA episodes, the number of bursts per hour of 
sleep, bursts per episode, episodes with sound, and the mean 
duration did not differ before and after BoNT-A injection. 
These results can be expected considering the pathophysiology 
of SB and the pharmacological actions of BoNT-A. RMMA 
episodes in SB have been shown to be generated by the central 
commands in relation to transient arousals.28,29 On the other 
hand, BoNT-A prevents synaptic transmissions at the neuro-
muscular junctions, which results in a decrease of compound 
muscle action potentials.27 Thus, the injections of BoNT-A on 
jaw-closing muscles failed to the prevent the genesis of RMMA 
episodes and OFAs during sleep. But, this study demonstrated 
the reducing effects of BoNT-A on the intensity of muscle 
contractions during sleep: the peak amplitude of EMG bursts 
during RMMA episodes decreased in the muscles with BoNT-A 
injection, i.e., masseter in group A and the masseter and tempo-
ralis muscles in group B.
Tables 5—Orofacial activities
Orofacial activities
Pre-injection
(n = 20)
Post-injection
(n = 20) p
Lip-sucking/h 0.52 ± 0.25 0.53 ± 0.25 0.999
Head movements/h 1.11 ± 1.58 0.74 ± 0.69 0.291
Chewing-like movements/h 0.84 ± 0.71 0.78 ± 0.69 0.847
Swallowing/h 1.96 ± 1.69 1.72 ± 1.69 0.511
Eye-opening/h 1.05 ± 0.25 0.44 ± 0.37 0.090
Data are mean ± standard deviation (paired t-test).
Table 6—Clinically subjective symptoms
Symptoms
MA injection
(Group A)
MA+TE 
injection
(Group B) p
Subjective bruxism event (n)
Decrease 4 5
Increase 0 0 1.000*
No change 6 5
Morning jaw stiffness (%) 47.50 ± 15.86 57.50 ± 30.30 0.371
Decrement of subjective 
masticatory force (%)
30.00 ± 17.64 40.50 ± 18.33 0.208
*The data were analyzed by χ2 test. Other data are mean ± standard 
deviation (paired t-test).
Table 4—The peak amplitude of EMG burst of the masseter and temporalis muscles during MVC tasks and during RMMA 
episodes
Peak EMG 
amplitude
MA injection (Group A) MA+TE injection (Group B)
p†Pre Post p* Pre Post p*
MVC MA (μV) 216.30 (39.00, 800.50) 43.10 (26.70, 130.10) < 0.001 223.15 (81.20, 333.80) 78.00 (34.20, 169.10) < 0.001 0.185
MVC TE (μV) 169.72 (105.50, 515.50) 171.05 (64.70, 414.00) 0.254 226.35 (104.90, 432.90) 104.45 (40.20, 218.20) 0.002 0.010
RMMA MA (μV) 290.47 (31.12, 741.62) 72.41 (29.41, 141.58) 0.001 215.71 (114.32, 390.86) 72.30 (32.87, 98.90) < 0.001 0.916
RMMA TE (μV) 277.63 (87.42, 553.53) 194.80 (45.00, 383.95) 0.210 306.41 (160.99, 377.71) 83.00 (17.24, 283.44) 0.001 0.025
MA, masseter muscle; TE, temporalis muscle; MVC, maximal voluntary clenching; RMMA, rhythmic masticatory muscle activity. Data are presented as 
median (range) values and underwent log transformation for normal distribution. *Comparison for the change between pre- and post-BoNT-A injection in 
each group using paired t-test. †Intergroup comparison for the change between pre- and post-BoNT-A injection (repeated-measures ANOVA). p < 0.05 was 
considered significant (bold type).
296Journal of Clinical Sleep Medicine, Vol. 10, No. 3, 2014
YJ Shim, MK Lee, T Kato et al
Our results are inconsistent with those of a previous study 
in which the number of masticatory EMG bursts decreased by 
BoNT-injection.19 The discrepancy is explained by the method-
ological difference between our study and the previous study; 
in the previous study, the occurrences of EMG bursts were 
assessed by ambulatory EMG recording system.19 It is difficult 
for ambulatory EMG recordings system to detect RMMA EMG 
bursts with a amplitude lower than the predetermined EMG 
threshold after injection,20 whereas the use of vPSG in this 
study allowed us to avoid the underestimation of the jaw motor 
activity after injections. Nevertheless, the results of our study 
and the previous study suggest that BoNT-A injections decrease 
the number of intense jaw motor activities during sleep.
No significant differences were found for RMMA episodes 
between groups A (only masseter muscle) and B (both masseter 
and temporalis muscles). A difference was found only at 
the peak amplitude of EMG burst of the temporalis muscles 
during RMMA episodes. Although it is not known which 
muscle (temporalis or masseter) is more engaged with the act 
of RMMA, no significant difference was found for the peak 
amplitude of EMG burst during RMMA episodes before injec-
tion between the masseter and temporalis muscles (p = 0.433). 
There is a clinical suggestion that bilateral BoNT injections 
to the temporalis muscles are the first-line recommendation 
for the management of SB when single muscle injection is 
the clinical plan.30 The importance of controlling the tempo-
ralis muscle activity for managing SB needs further investiga-
tion. However, when compared with single muscle injection, 
injections into both muscles would have more reducing effects 
on total occlusal loads during RMMA episodes, as both the 
masseter and temporalis muscles contract synergistically to 
produce masticatory force.
BoNT-A Injection
In this study, the injection sites were selected based on 
previous studies.21-23 In the BoNT injection procedure, the most 
effective point of injection is the area where the appropriate 
nerve innervates the affected muscle. The bulky region of the 
masseter and temporalis muscles has been regarded as an effec-
tive injection point clinically as the richest arborized area of 
the perforating nerve branches.21-23 Previous studies reporting 
the effect of BoNT-A on bruxism used dose ranging from 15 to 
60 U (equivalent to those of Neuronox).11-19 Kim et al. showed 
that the effects of BoNT-A on the muscular thickness and 
EMG changes of the masseter muscle did not differ between 
25 and 35 U injections.31 Therefore, only 25 U of BoNT-A was 
chosen for the present study. In addition, the reducing effect on 
the masticatory force was maximal at 4 weeks after BoNT-A 
injection,31-33 and the maximum bite force gradually recovered 
within 12 weeks. So, we evaluated the effect of BoNT-A on 
RMMA episodes during sleep at the point when the maximum 
effect was exerted.
Effects of BoNT Injection on Sleep
There were no significant differences in usual sleep variables 
such as sleep efficiency, arousal index, sleep stages, or awaken-
ings per hour between baseline and follow-up recordings. Simi-
larly to this, oral splint treatment had no influence on the sleep 
variables in the previous study.9 RMMA is associated with 
autonomic sympathetic cardiac activity and sleep arousals char-
acterized by increased EEG, muscle and heart activity without 
return to consciousness.2,8 As BoNT injection cannot modulate 
the sleep arousals, the only EMG amplitude of injected muscle 
was decreased after BoNT injection in this study. However, it 
is not known whether a decreased intensity of muscle contrac-
tion modifies the accompanying cardiac and cortical activi-
ties related to arousals during sleep. To clarify this, we need 
to quantitatively analyze the change of cortical EEG and heart 
rates related to RMMA episodes before and after BoNT injec-
tion in the further study.
Subjective Symptoms
Although BoNT-A reduced the intensity of muscle contrac-
tions during sleep, the same effects presented during waking 
oral functions as shown in the data for the peak amplitude of 
EMG burst during MVC. It is known that muscle weakness is 
a medication-related side effect. In this study, fourteen subjects 
reported discomfort associated with a decrease of the sensa-
tion in the masticatory force after injection; among them, three 
subjects complained of masticatory difficulties. This side effect 
was well tolerated by subjects probably because of the compen-
sation mechanisms by other jaw muscles (e.g., medial ptery-
goid muscle) in jaw movements. Masticatory muscle weakness 
can recover gradually from 4 to 12 weeks after BoNT injection 
in association with the changes of masticatory force.32,33
In association with a decrease in the peak amplitude of EMG 
burst of RMMA episodes, the BoNT-A injection improved 
the subjective symptoms for morning jaw stiffness and tooth 
grinding during sleep. Morning jaw stiffness is commonly 
reported by the subjects with frequent RMMA episodes.34,35 
Morning symptoms are thought to be a form of post-exercise 
muscle soreness caused by intense jaw muscle contractions 
during sleep.36 Thus the results might suggest that the subjects 
perceived less muscle fatigue in the morning in relation to the 
decreased motor activities during sleep. The most frequently 
cited theory is that the masticatory muscle pain and dysfunc-
tion are caused by muscle hyperactivity. But it is questionable 
because EMG studies of the masticatory muscles in patients 
with myofascial pain (MFP) do not always show an increase 
in resting muscle activity. So, there was an opinion that BoNT 
should not be used for the treatment of MFP involving the 
masticatory muscles.37 However, there was a report that MFP 
symptoms in bruxers were reduced after BoNT-A injection.18,38 
Although there are insufficient systematic evaluation of the 
effect of BoNT-A on masticatory muscle pain and the subjective 
symptoms are probably overevaluated, it is helpful in relieving 
subjective symptoms of morning jaw stiffness in our subjects 
who still reported morning jaw stiffness after the oral splint 
treatment. Further controlled studies with placebo injections 
are needed to investigate whether BoNT-A injection reduces 
the risk of muscle pain symptoms by decreasing masseter 
and temporalis muscle forces during sleep with systematic 
evaluations of pain.
Study Limitations
There were several limitations to our study. First, most of the 
subjects in our study had a low frequency of RMMA episodes 
(e.g., mild level according to the previous publication34), 
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although subjects who failed usual oral splint treatment for SB 
were selected on the clinical signs and symptoms of SB. Among 
20 subjects, 15 complained of pain and fatigue of masticatory 
muscles, and all reported morning jaw stiffness. SB patients 
with low frequency of RMMA episodes were more at risk of 
reporting pain in the masticatory muscles.34,39 Thus, the treat-
ment responses to BoNT-A injections may be influenced by 
the severity of SB and concomitant pain conditions. Second, 
a lack of control group (i.e., placebo injection) and systematic 
assessment of masticatory muscle pain at a follow-up period 
would obscure the effects of BoNT-A on subjective symptoms 
in association with PSG data. Third, the sample size in the 
present study was small, due to the high cost and difficulties 
of patient recruitment. Fourth, PSG evaluation was done for 
one night at baseline. There might be first-night effects on the 
occurrence of RMMA, and night-to-night variability of RMMA 
is also known.2,40 However, the influences of such factors seem 
to be minimal, since no major difference was found for sleep 
variables between the two recordings. Assessment of long-
term effects also should be considered. The effects of single 
BoNT-A injection to the masticatory force lasted from 2 weeks 
to up to 24 weeks,33 and the effects started to decline 4 weeks 
after injection. The previous study reported that the effects of a 
single BoNT-A injection on jaw muscle EMG activity persisted 
up to 12 weeks.2 It would therefore be better for future studies 
to include both 2-week and longer-term follow-ups (e.g., 8, 12, 
and 16 weeks). At last, in this study, the BoNT-A injection did 
not cause a significant side effect for at least a month. However, 
safety of the injections needs to be assessed on long term. Future 
studies should address the limitations of the present study.
In summary, this study is significant in being the first to 
evaluate the short-term effect of BoNT-A on SB using vPSG. 
We confirmed that BoNT-A did not change the occurrence 
but reduced the intensity of contractions for the masseter and 
temporalis muscles during sleep. Future studies are needed 
before BoNT-A will be safe and effective management 
option for controlling jaw motor activities during sleep in 
patients with SB and protecting the orofacial structures from 
the excessive forces.
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